Across TCGA pan-cancer cohorts, LINC00320 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated LINC00320 data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LINC00320 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC00320 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LGG show a favorable association.
LIHC, MESO, and LUAD are the cancer types where LINC00320 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.